 |
.
 |
News and Press Releases |
 |
Signant Health finds growing eConsent adoption forecasts and the importance of eClinical integration in latest “State of eConsent” survey
PHILADELPHIA, PA – January 16, 2020: Signant Health, released the
findings from its latest “State of eConsent” report today, highlighting
the sentiments, successes, and challenges of eConsent practitioners
around the world. Join Signant Health’s webinar on February 12, 2020 at
11am ET or 3pm ET to learn more about the findings.
More info >> |
|
.
 |
White Papers |
 |
|
Working Towards a Standardised Identification Solution
PCI Pharma Services
The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >> |
|
 |
Industry Events |
 |
SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)
11-13 May 2020, Copthorne Tara Hotel, London, UK
SMi is delighted to announce its 4th Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 11th – 12th May 2020.
HPAPI 2020 conference focuses on the growing landscape driven by the demand for highly potent drugs in oncology, diabetes and autoimmune disease treatment. This event will address the biggest challenges the industry is facing with regards to determining toxicology limits, assessing hazards, implementing risk procures, translating risk assessment into facility engineering, preventing and dealing with cross-contamination and adhering to GMP regulatory guidelines.
More info >> |
|
|
